Bionomics Ltd ADR
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $1.6901
- Today's High:
- $1.9193
- Open Price:
- $1.89
- 52W Low:
- $1.8
- 52W High:
- $10.9
- Prev. Close:
- $1.86
- Volume:
- 163952
Company Statistics
- Market Cap.:
- $20.48 million
- Book Value:
- 5.76
- Revenue TTM:
- $6.02 million
- Operating Margin TTM:
- -346.16%
- Gross Profit TTM:
- $-9943677
- Profit Margin:
- 0%
- Return on Assets TTM:
- -20.98%
- Return on Equity TTM:
- -46.14%
Company Profile
Bionomics Ltd ADR had its IPO on 2021-12-16 under the ticker symbol BNOX.
The company operates in the Healthcare sector and Biotechnology industry. Bionomics Ltd ADR has a staff strength of 0 employees.
Stock update
Shares of Bionomics Ltd ADR opened at $1.89 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $1.69 - $1.92, and closed at $1.76.
This is a -5.38% slip from the previous day's closing price.
A total volume of 163,952 shares were traded at the close of the day’s session.
In the last one week, shares of Bionomics Ltd ADR have slipped by -10.66%.
Bionomics Ltd ADR's Key Ratios
Bionomics Ltd ADR has a market cap of $20.48 million, indicating a price to book ratio of 1.3059 and a price to sales ratio of 8.4433.
In the last 12-months Bionomics Ltd ADR’s revenue was $6.02 million with a gross profit of $-9943677 and an EBITDA of $-19929630. The EBITDA ratio measures Bionomics Ltd ADR's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Bionomics Ltd ADR’s operating margin was -346.16% while its return on assets stood at -20.98% with a return of equity of -46.14%.
In Q1, Bionomics Ltd ADR’s quarterly earnings growth was a positive 0% while revenue growth was a negative 21.6%.
Bionomics Ltd ADR’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-2.17 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Bionomics Ltd ADR’s profitability.
Bionomics Ltd ADR stock is trading at a EV to sales ratio of 97.877 and a EV to EBITDA ratio of -1.1769. Its price to sales ratio in the trailing 12-months stood at 8.4433.
Bionomics Ltd ADR stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $16.33 million
- Total Liabilities
- $838910.00
- Operating Cash Flow
- $0
- Capital Expenditure
- $158095.75
- Dividend Payout Ratio
- 0%
Bionomics Ltd ADR ended 2024 with $16.33 million in total assets and $0 in total liabilities. Its intangible assets were valued at $16.33 million while shareholder equity stood at $14.23 million.
Bionomics Ltd ADR ended 2024 with $0 in deferred long-term liabilities, $838910.00 in other current liabilities, 54423939.75 in common stock, $-43326625.75 in retained earnings and $3.22 million in goodwill. Its cash balance stood at $8.39 million and cash and short-term investments were $8.39 million. The company’s total short-term debt was $127,100 while long-term debt stood at $0.
Bionomics Ltd ADR’s total current assets stands at $10.45 million while long-term investments were $0 and short-term investments were $6559.00. Its net receivables were $1.70 million compared to accounts payable of $389220.25 and inventory worth $7767.25.
In 2024, Bionomics Ltd ADR's operating cash flow was $0 while its capital expenditure stood at $158095.75.
Comparatively, Bionomics Ltd ADR paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $1.76
- 52-Week High
- $10.9
- 52-Week Low
- $1.8
- Analyst Target Price
- $7
Bionomics Ltd ADR stock is currently trading at $1.76 per share. It touched a 52-week high of $10.9 and a 52-week low of $10.9. Analysts tracking the stock have a 12-month average target price of $7.
Its 50-day moving average was $1.9 and 200-day moving average was $3.09 The short ratio stood at 0.54 indicating a short percent outstanding of 0%.
Around 0% of the company’s stock are held by insiders while 776.7% are held by institutions.
Frequently Asked Questions About Bionomics Ltd ADR
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company’s lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder. It also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia. Bionomics Limited was incorporated in 1996 and is based in Eastwood, Australia.